Inceptive
Palo Alto, US · 6 known investors
Inceptive builds foundation models of biological systems for drug discovery, specializing in sequence-based medicines like mRNA and peptides. The company combines deep learning trained on heterogeneous life data with in-house wet lab validation to design novel drug candidates that outperform existing options.
Founders & leadership
JU
Jakob UszkoreitExecutive Officer, Director, Promoter
KH
Kevin HeyriesExecutive Officer
VS
Vijay S. PandeDirector
DI
Diana Isabel AjuriaExecutive Officer
DS
Do Soon KimExecutive Officer
Investors · 6
Reported raises · per SEC filings
Form D private placements▶$99.7MraisedSep 2023 · 8 investors · OtherRule 506(b)
▶$99.7MraisedSep 2023 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jakob UszkoreitExecutive Officer, Director, Promoter
- Kevin HeyriesExecutive Officer
- Vijay S. PandeDirector
- Diana Isabel AjuriaExecutive Officer
- Do Soon KimExecutive Officer
- Offering amount
- $100M
- Amount sold
- $99.7M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- BridgeBio Secures $1 Billion Investment to Strengthen Capital Structure | Intellectiaintellectia.ai · 2026
- Alnylam expands AI partnership with Komodo Health By Investing.comza.investing.com · 2026
- Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock - Insider Monkeyinsidermonkey.com · 2026
- City raises $99.5M to 'expand where RNAi medicines can go and what they can achieve' | FirstWord Pharmafirstwordpharma.com · 2026
- Q3 2023 Quarterly Insights — Dynamk Capitaldynamk.vc · 2023